We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Worm-on-a-Chip Device Could Noninvasively Diagnose Early-Stage Cancer

By LabMedica International staff writers
Posted on 22 Mar 2022

Dogs can use their incredible sense of smell to sniff out various forms of cancer in human breath, blood and urine samples. More...

Similarly, in the lab a much simpler organism, the roundworm C. elegans, wriggles its way toward cancer cells by following an odor trail. Scientists have now reported a device that uses the tiny worms to detect lung cancer cells.

This “worm-on-a-chip” developed by researchers at the Myongji University (Seoul, Korea) could someday help doctors noninvasively diagnose cancer at an earlier stage. Early diagnosis of cancer is critical for effective treatment and survival. Therefore, cancer screening methods should be quick, easy, economical and noninvasive. Currently, doctors diagnose lung cancer by imaging tests or biopsies, but these methods often can’t detect tumors at their earliest stages. Although dogs can be trained to sniff out human cancer, they aren’t practical to keep in labs. So the researchers decided to use worms called nematodes, which are tiny (~1 mm in length), easy to grow in the lab and have an extraordinary sense of smell, to develop a noninvasive cancer diagnostic test.

Other researchers have placed nematodes in petri dishes and added drops of human urine, observing that the worms preferentially crawled toward urine samples from cancer patients. Jang and Choi wanted to make an accurate, easy-to-measure form of the test. The team at Myongji University made a chip out of polydimethylsiloxane elastomer that had a well at each end connected by channels to a central chamber. The researchers placed the chip on an agar plate. At one end of the chip, they added a drop of culture media from lung cancer cells, and at the other end, they added media from normal lung fibroblasts. They placed worms in the central chamber, and after an hour, they observed that more worms had crawled toward the lung cancer media than the normal media. In contrast, worms that had a mutated odor receptor gene called odr-3 did not show this preferential behavior.

Based on these tests, the researchers estimated that the device was about 70% effective at detecting cancer cells in diluted cell culture media. They hope to increase both the accuracy and sensitivity of the method by using worms that were previously exposed to cancer cell media and therefore have a “memory” of cancer-specific odor molecules. Once the team has optimized the worm-on-a-chip for detecting cultured lung cancer cells, they plan to move on to testing urine, saliva or even exhaled breath from people. They also plan to test the device on multiple forms of cancer. In other studies using the worm-on-a-chip, the researchers identified the specific odor molecules that attract C. elegans to lung cancer cells, including a volatile organic compound called 2-ethyl-1-hexanol, which has a floral scent.

“Lung cancer cells produce a different set of odor molecules than normal cells,” said Shin Sik Choi, Ph.D. at Myongji University who was the project’s principal investigator. “It’s well known that the soil-dwelling nematode, C. elegans, is attracted or repelled by certain odors, so we came up with an idea that the roundworm could be used to detect lung cancer.”

Related Links:
Myongji University 


New
Gold Member
Automated MALDI-TOF MS System
EXS 3000
Collection and Transport System
PurSafe Plus®
Gel Cards
DG Gel Cards
6 Part Hematology Analyzer with RET + IPF
Mispa HX 88
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: New evidence shows viscoelastic testing can improve assessment of blood clotting during postpartum hemorrhage (Photo courtesy of 123RF)

Viscoelastic Testing Could Improve Treatment of Maternal Hemorrhage

Postpartum hemorrhage, severe bleeding after childbirth, remains one of the leading causes of maternal mortality worldwide, yet many of these deaths are preventable. Standard care can be hindered by delays... Read more

Immunology

view channel
Image: The CloneSeq-SV approach can allow researchers to study how cells within high-grade serous ovarian cancer change over time (Photo courtesy of MSK)

Blood Test Tracks Treatment Resistance in High-Grade Serous Ovarian Cancer

High-grade serous ovarian cancer (HGSOC) is often diagnosed at an advanced stage because it spreads microscopically throughout the abdomen, and although initial surgery and chemotherapy can work, most... Read more

Pathology

view channel
Image: The new system allows surgeons to identify genotyping of brain tumors and determine optimal resection margins during surgery (Photo courtesy of Nagoya University)

New Technique Detects Genetic Mutations in Brain Tumors During Surgery within 25 Minutes

Determining the genetic profile of brain tumors during surgery is crucial for improving patient outcomes, but conventional analysis methods can take up to two days, delaying critical decisions.... Read more

Industry

view channel
Image: The enhanced collaboration builds upon the successful launch of the AmplideX Nanopore Carrier Plus Kit in March 2025 (Photo courtesy of Bio-Techne)

Bio-Techne and Oxford Nanopore to Accelerate Development of Genetics Portfolio

Bio-Techne Corporation (Minneapolis, MN, USA) has expanded its agreement with Oxford Nanopore Technologies (Oxford, UK) to broaden Bio-Techne's ability to develop a portfolio of genetic products on Oxford... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.